Our data suggest that AMPK activation in the liver could be beneficial by opposing short-term glucagon action via PDE activation to reduce cAMP as a new therapeutic strategy for the treatment of metabolic diseases associated with dysregulated cAMP/PKA signalling, such as type 2 diabetes. This evidence concerns the gene ALDH7A1 and type 2 diabetes mellitus.